Adverse effects and complications of continuous intestinal infusion of levodopa-carbidopa in a cohort of patients with Parkinson's disease in a tertiary hospital
INTRODUCTION: Continuous intestinal infusion of levodopa/carbidopa is a second-line treatment indicated in advanced stages of Parkinson's disease (PD). For its implantation, a percutaneous endoscopic gastrostomy must be performed.
OBJECTIVES: The main objective has been to describe the frequency and characteristics of the side effects associated with this treatment. As a secondary objective, we have analyzed the epidemiological and clinical characteristics of the PD patients who have received this treatment in our hospital.
PATIENTS AND METHODS: Descriptive, single-center, retrospective study for a consecutive sample of PD patients treated with Continuous intestinal infusion of Levodopa/Carbidopa from the beginning of 2006 to the end of August 2021.
RESULTS: 81 treatment planifications have been analyzed. Treatment success (duration greater than 12 months) was achieved in 78.1% (n = 50) of the patients in whom this follow-up period was available. The median duration of treatment was 35 months. 58.6% of the patients presented some type of complication. A total of 43 minor complications and 16 serious adverse events were reported.
CONCLUSION: The constitution of an experienced multidisciplinary team is essential to guarantee the adequate management and follow-up of these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Revista de neurologia - 74(2022), 5 vom: 01. März, Seite 143-148 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Efectos adversos y complicaciones de la infusión intestinal continua de levodopa-carbidopa en una cohorte de pacientes con enfermedad de Parkinson de un hospital terciario |
|---|
| Beteiligte Personen: |
Campins-Romeu, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
46627O600J |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 05.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.33588/rn.7405.2021482 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337434794 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337434794 | ||
| 003 | DE-627 | ||
| 005 | 20231225234411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.33588/rn.7405.2021482 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337434794 | ||
| 035 | |a (NLM)35211947 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Campins-Romeu, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse effects and complications of continuous intestinal infusion of levodopa-carbidopa in a cohort of patients with Parkinson's disease in a tertiary hospital |
| 246 | 3 | 3 | |a Efectos adversos y complicaciones de la infusión intestinal continua de levodopa-carbidopa en una cohorte de pacientes con enfermedad de Parkinson de un hospital terciario |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 05.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Continuous intestinal infusion of levodopa/carbidopa is a second-line treatment indicated in advanced stages of Parkinson's disease (PD). For its implantation, a percutaneous endoscopic gastrostomy must be performed | ||
| 520 | |a OBJECTIVES: The main objective has been to describe the frequency and characteristics of the side effects associated with this treatment. As a secondary objective, we have analyzed the epidemiological and clinical characteristics of the PD patients who have received this treatment in our hospital | ||
| 520 | |a PATIENTS AND METHODS: Descriptive, single-center, retrospective study for a consecutive sample of PD patients treated with Continuous intestinal infusion of Levodopa/Carbidopa from the beginning of 2006 to the end of August 2021 | ||
| 520 | |a RESULTS: 81 treatment planifications have been analyzed. Treatment success (duration greater than 12 months) was achieved in 78.1% (n = 50) of the patients in whom this follow-up period was available. The median duration of treatment was 35 months. 58.6% of the patients presented some type of complication. A total of 43 minor complications and 16 serious adverse events were reported | ||
| 520 | |a CONCLUSION: The constitution of an experienced multidisciplinary team is essential to guarantee the adequate management and follow-up of these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antiparkinson Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Gels |2 NLM | |
| 650 | 7 | |a Levodopa |2 NLM | |
| 650 | 7 | |a 46627O600J |2 NLM | |
| 650 | 7 | |a Carbidopa |2 NLM | |
| 650 | 7 | |a MNX7R8C5VO |2 NLM | |
| 700 | 1 | |a Sastre-Bataller, I |e verfasserin |4 aut | |
| 700 | 1 | |a Pons-Beltrán, V |e verfasserin |4 aut | |
| 700 | 1 | |a Baviera-Muñoz, R |e verfasserin |4 aut | |
| 700 | 1 | |a Losada-López, M |e verfasserin |4 aut | |
| 700 | 1 | |a Morata-Martínez, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-García, J |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Torres, I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista de neurologia |d 1994 |g 74(2022), 5 vom: 01. März, Seite 143-148 |w (DE-627)NLM074738666 |x 1576-6578 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:5 |g day:01 |g month:03 |g pages:143-148 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.33588/rn.7405.2021482 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 5 |b 01 |c 03 |h 143-148 | ||